Analysis of phenolic content and antioxidant activity of cocoa pod husk (theobroma cacao l.)

Abstract:This research has been conducted to measure the total of phenolic content and the test of antioxidant activity in cocoa pod husk. Cocoa pod husk extract was obtained by maceration using 2 kinds of solvents, they are 70% ethanol and acetone: water (7: 3). Folin Ciocalteu method was used to measure the total of phenolic compounds and DPPH (1,1- diphenyl-2-pikrilhidrazil) method was used to measure the antioxidant activity. The results obtained, the total phenolic content of 70% ethanol extract and acetone extract: water (7: 3) respectively had the following values: 94.92 GAE/g, 49.92 GAE/g. while the antioxidant activity of 70% ethanol extract and acetone extract: water respectively had the following values: 88.16%, 44.11%

The effect of different substrates on oyster mushroom (Pleurotus ostreatus) spawn growth

The study aimed to find alternative substrates for growing spawn of oyster mushroom (Pleurotus ostreatus). The experiment was laid out in a completely randomized design with three compositions of substrates. The substrate compositions were: (1) Substrate A (corn 100%), (2) Substrate B (corn and sawdust mix in a ratio of (1:1, v/v)), and (3) Substrate C (corn and sawdust mix in a ratio of (3:1, v/v)). All compositions were replicated 18 times. The complete colonization (days) and mycelium growth rate (cm day-1) were recorded. Means were analyzed by Analysis of Variance (ANOVA) and duncan test was performed if there were significant between the substrate compositions. The results showed that substrate C was the best substrate indicated with the fastest complete colonization of 14.17±0.92 and the highest growth rate of 0.85±0.06 cm day-1

Global Retinoblastoma Presentation and Analysis by National Income Level

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- A nd middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs

Global Retinoblastoma Presentation and Analysis by National Income Level.

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs

Global Retinoblastoma Presentation and Analysis by National Income Level

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4) were female. Most patients (n = 3685 84.7%) were from low-and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 62.8%), followed by strabismus (n = 429 10.2%) and proptosis (n = 309 7.4%). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 95% CI, 12.94-24.80, and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 95% CI, 4.30-7.68). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs. © 2020 American Medical Association. All rights reserved

Perbedaan Ekstrak Etanol dan Etil Asetat Daun Lada (Piper nigrum L) terhadap Aktivitas Antimikroba

Penelitian ini bertujuan untuk mengetahui perbedaan ekstrak etanol dan ekstrak etil asetat daun lada (Piper nigrum L) terhadap aktivitas antimikroba Staphylococcua aureus, Escherichia coli dan Candida albicans. Metode maserasi telah digunakan untuk mengekstrak daun lada dengan menggunakan dua pelarut yaitu etanol 70% dan etil asetat. Hasil ekstrak selanjutnya dilakukan uji aktivitas antimikroba. Hasil ekstrak etanol daun lada diperoleh rendemen yang lebih tinggi yaitu 24,64% dibandingkan dengan ekstrak etil asetat 9,18%. Ekstrak etanol daun lada memiliki aktivitas antimikroba lebih tinggi dibandingkan ekstrak etil asetat daun lada terhadap bakteri Staphylococcua aureus,dan Escherichia coli tetapi tidak menghambat jamur Candida albicans  pada konsentrasi 10%

Ekspresi Gen P53 pada Pterigium Primer dan Pterigium Rekuren

The purpose of the present study was to identify  and  compare the mutant P53 expression in primary and recurrent pterygium. The method of the study was observational analytic cross- sectional study with 19 samples of primary pterygium and 19 samples recurrent pterygium. Data obtained with pterygium tissue sampling then performed with immunohistochemical examination. Results The Study was conducted for 5 month with 19 samples of primary pterygium and 19 samples of recurrent pterygium. From the overall data shown that P53 expression of primary and recurrent pterygium average 191.6 while there is 38.3 for primary pterygium and 344.8 for recurrent pterygium.  There were significant differences between the expression of P53 of primary and P53 expression of recurrent pterygium with (P = 0.000). Conclusions is There was no significant difference in the mean expression of P53 according to the stage of pterygium although there was a tendency of P53 expression of getting smaller with increasing stage of pterygium

The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries

Retinoblastoma is the most common intraocular cancer worldwide. There is some evidence to suggest that major differences exist in treatment outcomes for children with retinoblastoma from different regions, but these differences have not been assessed on a global scale. We aimed to report 3-year outcomes for children with retinoblastoma globally and to investigate factors associated with survival